Research
Hormonal
Tirzepatide 10 mg is the most cost-efficient dose for achieving moderate weight loss targets (10% and 15%) and provides competitive outcomes for BMI improvement compared to 5mg and 15mg doses.
For patients targeting moderate weight loss (10-15%), the 10mg weekly dose of tirzepatide offers a strong balance of efficacy and cost-efficiency, often outperforming lower doses and competing well with higher doses for BMI improvements.
GoodSupportsHIGH confidence
Tirzepatide 10 mg showed good cost-efficiency for achieving 10% and 15% weight loss based on the cost analysis and generally demonstrated competitive outcomes compared to tirzepatide 5 mg and tirzepatide 15 mg across different BMI improvement categories...
Why this rating
Based on the same high-quality trial data.
Source
Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study
Marc Evans et al. · Advances in Therapy · 2025
DOI 10.1007/s12325-025-03194-8
rct · n=2539Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →